- Home
- CEE vs OPTN Comparison
CEE vs OPTN Comparison
Compare CEE & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEE
- OPTN
- Stock Information
- Founded
- CEE 1990
- OPTN 2010
- Country
- CEE Germany
- OPTN United States
- Employees
- CEE N/A
- OPTN N/A
- Industry
- CEE Finance Companies
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- CEE Finance
- OPTN Health Care
- Exchange
- CEE Nasdaq
- OPTN Nasdaq
- Market Cap
- CEE 83.8M
- OPTN 92.8M
- IPO Year
- CEE N/A
- OPTN 2017
- Fundamental
- Price
- CEE $15.48
- OPTN $9.69
- Analyst Decision
- CEE
- OPTN Hold
- Analyst Count
- CEE 0
- OPTN 3
- Target Price
- CEE N/A
- OPTN $9.00
- AVG Volume (30 Days)
- CEE 22.0K
- OPTN 21.6K
- Earning Date
- CEE 01-01-0001
- OPTN 05-27-2025
- Dividend Yield
- CEE 3.86%
- OPTN N/A
- EPS Growth
- CEE N/A
- OPTN N/A
- EPS
- CEE N/A
- OPTN N/A
- Revenue
- CEE N/A
- OPTN $81,856,000.00
- Revenue This Year
- CEE N/A
- OPTN $30.49
- Revenue Next Year
- CEE N/A
- OPTN $13.51
- P/E Ratio
- CEE N/A
- OPTN N/A
- Revenue Growth
- CEE N/A
- OPTN 10.20
- 52 Week Low
- CEE $7.80
- OPTN $4.82
- 52 Week High
- CEE $10.32
- OPTN $20.03
- Technical
- Relative Strength Index (RSI)
- CEE 63.77
- OPTN 82.67
- Support Level
- CEE $15.32
- OPTN $9.37
- Resistance Level
- CEE $15.74
- OPTN $9.45
- Average True Range (ATR)
- CEE 0.33
- OPTN 0.08
- MACD
- CEE 0.08
- OPTN -0.04
- Stochastic Oscillator
- CEE 78.63
- OPTN 89.13
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.